Dolutegravir Impact on Residual Replication: Dolutegravir Intensification Study

Trial Profile

Dolutegravir Impact on Residual Replication: Dolutegravir Intensification Study

Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Mar 2018

At a glance

  • Drugs Dolutegravir (Primary)
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms DIORR
  • Most Recent Events

    • 07 Mar 2018 Primary endpoint (Level of residual HIV replication in circulating CD4+ T cells) has not been met as per the results presented at the 25th Conference on Retroviruses and Opportunistic Infections.
    • 07 Mar 2018 Results presented at the 25th Conference on Retroviruses and Opportunistic Infections
    • 16 Nov 2017 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top